Durvalumab/Selumetinib sulfate

N/A

Report date: 2023/06/02 18:01:50

Base Information

Drug NameDurvalumab/Selumetinib sulfate
Drug Alias NameSelumetinib+DurvalumabDurvalumab and SelumetinibDurvalumab+SelumetinibSelumetinib/Durvalumab
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase 1 inhibitorsDual specificity mitogen-activated protein kinase kinase 2 inhibitorsProgrammed death-ligand 1 blockers
TargetsDual specificity mitogen-activated protein kinase kinase 2Programmed death-ligand 1Dual specificity mitogen-activated protein kinase kinase 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes DurvalumabSelumetinib sulfate
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A